Ratings by Morgan Stanley (Thibault Boutherin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/11/2026 | Novo Nordisk | NVO | Downgrade | Underweight (Equalweight) |
44.56 (43.07) |
-3.34% | Details | |
| 3/26/2026 | Novartis | NVS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/14/2025 | Alvotech SA | ALVO | Upgrade | Overweight (Equalweight) |
8.24 (5.29) |
-35.8% | Details | |
| 8/8/2025 | Novartis | NVS | Upgrade | Equalweight (Underweight) |
113.50 (137.16) |
20.85% | Details | |
| 2/12/2025 | Alvotech SA | ALVO | Maintain | Equalweight (N/A) |
|
Details | ||
| 7/29/2024 | Evotec | EVO | Downgrade | Equalweight (Overweight) |
4.71 (1.73) |
-63.27% | Details | |
| 5/25/2023 | Teva Pharma | TEVA | New Coverage | Equalweight (N/A) |
7.57 (37.09) |
389.96% | Details | |
| 9/7/2022 | Alvotech SA | ALVO | New Coverage | Equalweight (N/A) |
7.56 (8.24) |
8.99% | Details |
